One Patient Got Retatrutide Before FDA Approval — and Why It's So Unusual

Our Take

What is "compassionate use"?

Compassionate use — formally called expanded access — is a route for patients with serious or life-threatening conditions to receive an investigational drug when they can't join a clinical trial and have no comparable approved option. It's mostly used for cancer and rare genetic diseases. Three parties have to agree: the patient's doctor requests it, the FDA reviews whether the benefits outweigh the risks, and the manufacturer decides whether it's willing to supply the drug.

Why this case raised questions

• The request was made in April 2026 by an NIH clinician for a 79-year-old patient with refractory obesity, obstructive sleep apnea, and pulmonary hypertension.
• Drugmakers have historically not granted expanded access for weight-loss medications — obesity experts said they'd never heard of it being done.
• Two of retatrutide's three hormone targets are already available in approved drugs, so the interest likely centered on the third — its glucagon-receptor action on the liver.
• One ethicist noted that compassionate use usually has an obvious rationale (a terminal illness, no alternatives) — and said this was the first case he could think of where that wasn't clearly true.
• A biotech consultant expects more expanded-access requests for weight-loss drugs going forward, as research widens into cardiovascular, kidney, and other obesity-related outcomes.

Where this fits

This sits alongside the CBS investigation elsewhere in this hub: both show how far ahead of approval demand for retatrutide has run. One covers the unregulated grey market; this one covers the rare official exception. Together they illustrate the same pressure — a drug with strong trial data that people want before the system is ready to provide it.

Retatrutide remains investigational. Eli Lilly has said it plans to file for FDA approval later in 2026; until then, this kind of single-patient access is the exception, not a route available to the public.

Disclaimer

Retatrutide is an investigational drug. It is not approved by the FDA and is not legally available outside clinical trials. This page is informational and is not medical advice or an offer to sell.